Gerresheimer’s sustainable solutions for biotech and pharma

1 and 2 February in Paris

The vials are depyrogenated, sterile, and ready-to-use for injectables of the highest quality and flexible through different packaging configurations. Photo Gerresheimer

Gerresheimer is presenting innovative, solution-oriented, and sustainable developments at Pharmapack 2023. The range includes solutions, products, and delivery systems for medications, vaccines, or highly effective biologics. 

The compatibility of innovation, solutions and sustainability are at the top of Gerresheimer’s agenda. The company is demonstrating this at Pharmapack with its new developments for primary packaging, drug delivery systems, and medical and diagnostic products. In addition, Gerresheimer focuses on the development of packaging and delivery solutions for newly developed biologics.

Pharmapack is taking place on 1 and 2 February in Paris at the Paris Expo, Porte de  Versailles. The Gerresheimer team will be present in Hall 7.2 at Stand B60/B64.  

Improving quality while reducing

Wenzel Novak, Senior Global director of Business Development MDS, will present the new EZ-Fill Smart Platform for Vials. It offers a powerful route for improving pharmaceutical manufacturing quality standards while reducing the Total Cost of Ownership (TCO). 

Gx RTF Vials

The vials are depyrogenated, sterile, and ready-to-use for injectables of the highest quality and flexible through different packaging configurations including SG EZ-fill packaging format. They are produced according to cGMP, washed in a cleanroom, packed in a tray or nest and tub, and sterilized, ready to fill. They are also available as Elite glass vials. 

Due to the ready-to-fill status, the customer can proceed without the following steps: no need for washing and sterilization. This means no need to invest in machinery and manpower. Due to many years of experience in the area of prefillable primary packaging, Gerresheimer can minimize risks for the customers which could occur with sterile packaging. The Gx RTF injection vials are made of borosilicate glass type I and meet all common requirements of the applicable ISO standards and pharmacopeias, the company said.  

Gx InnoSafe

Nurses are among the occupational groups with the most frequent cuts and puncture wounds. This can lead to infection with dangerous pathogens such as hepatitis B and C viruses or HIV. The Gx InnoSafe safety syringe is the first syringe on the market with a passive needle protection system.

Its function prevents anyone from accidentally injuring themselves through an unintentional needle stick on a syringe that has already been used, as the needle is fixed in a sleeve after use. In addition to these unique safety features, a special feature of the Gx InnoSafe syringe is that it can be processed on all existing filling lines without any additional preparation or conversion steps. Furthermore,  it complies with all regulations without any additional investment.   


With DropControl, Gerresheimer has developed a new dropper insert for modern drugs with low viscosity for ophthalmology, which prevents the drug from flowing out uncontrollably during use. The new generation of eye-drop solutions has modified properties compared to the former water-based eye-drop solutions to improve efficiency and pharmaceutical effectiveness. For such eye-drop formulations, the function of a conventional eyedropper requires a modification to prevent uncontrolled dropping when the patient turns the eyedropper to release the droplets.

Gerresheimer is a global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems.


Please enter your comment!
Please enter your name here